Madrigal reports Q4 2022 cash $358.8M; positive Phase 3 NASH results support H1 2023 NDA filing

MADRIGAL PHARMACEUTICALS, INC.

2022-FY EPS reported -$17.23

Cash, cash equivalents and marketable securities $358.8M at Dec 31, 2022, up from $270.3M at Dec 31, 2021.
Operating expenses $85.3M (Q4) and $293.6M (FY2022), vs $64.6M and $242.5M in prior year periods.
R&D expenses $70.7M (Q4) and $245.4M (FY2022), increases due to Phase 3 trials and headcount.
Positive Phase 3 MAESTRO-NASH results achieved both primary endpoints; NDA filing for resmetirom planned H1 2023.
Secured $250M term loan facility with Hercules Capital and $300M+ in financing events in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.